Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline‐induced pulmonary hypertension in rats

@article{Alencar2013BeneficialEO,
  title={Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline‐induced pulmonary hypertension in rats},
  author={Allan K. N. Alencar and S. L. Pereira and T. Montagnoli and R. Maia and A. K{\"u}mmerle and S. S. Landgraf and C. Caruso-Neves and E. B. Ferraz and R. Tesch and J. Nascimento and Carlos M R Sant'Anna and Carlos A M Fraga and E. Barreiro and R. T. Sudo and G. Zapata-sudo},
  journal={British Journal of Pharmacology},
  year={2013},
  volume={169}
}
Pulmonary arterial hypertension (PAH) is characterized by enhanced pulmonary vascular resistance, right ventricular hypertrophy and increased right ventricular systolic pressure. Here, we investigated the effects of a N‐acylhydrazone derivative, 3,4‐dimethoxyphenyl‐N‐methyl‐benzoylhydrazide (LASSBio‐1359), on monocrotaline (MCT)‐induced pulmonary hypertension in rats. 
N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity.
Adenosine Receptors As Drug Targets for Treatment of Pulmonary Arterial Hypertension
Activation of GPER ameliorates experimental pulmonary hypertension in male rats
Purinergic dysregulation in pulmonary hypertension.
...
1
2
3
4
...

References

SHOWING 1-10 OF 268 REFERENCES
N-acylhydrazone derivative ameliorates monocrotaline-induced pulmonary hypertension through the modulation of adenosine AA2R activity.
Ruscogenin attenuates monocrotaline-induced pulmonary hypertension in rats.
Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues.
Targeted therapies in pulmonary arterial hypertension.
Pathways in pulmonary arterial hypertension: the future is here
...
1
2
3
4
5
...